Ibiglustat succinate
Modify Date: 2024-01-10 00:23:49
Ibiglustat succinate structure
|
Common Name | Ibiglustat succinate | ||
|---|---|---|---|---|
| CAS Number | 1629063-80-4 | Molecular Weight | 507.57 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H30FN3O6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Ibiglustat succinateIbiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2]. |
| Name | Ibiglustat succinate |
|---|
| Description | Ibiglustat (Venglustat) succinate is an orally active, brain-penetrant glucosylceramide synthase (GCS) inhibitor. Ibiglustat succinate can be used for the research of Gaucher disease type 3, Parkinson's disease associated with GBA mutations, Fabry disease, GM2 gangliosidosis, and autosomal dominant polycystic kidney disease[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Ibiglustat (SAR402671) succinate (1 μM, 15 days; Fabry disease (FD) cells) is close to the physiological level in untreated WT cells in GL-3 levels, suggesting that Ibiglustat succinate can prevent additional GL-3 accumulation and could serve to ameliorate the abundant levels of this sphingolipid in FD cardiomyocytes[4]. |
| References |
| Molecular Formula | C24H30FN3O6S |
|---|---|
| Molecular Weight | 507.57 |